Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06682481

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function: From Mice to Children

Status
Recruiting
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Philippe Klee, MD-PhD · Academic / Other
Sex
All
Age
12 Years – 16 Years
Healthy volunteers
Not accepted

Summary

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

Detailed description

One-center prospective study performed in collaboration between the Pediatric Endocrine and Diabetology unit of the University Hospitals of Geneva (HUG) and Prof. Pierre Maechler, Diabetes Center of the Faculty of Medicine, University of Geneva Switzerland. 1,5-anhydroglucitol (1,5-AG), a deoxyhexose present in almost all foods and forming a stable pool in human subjects, has recently been found to be correlated with functional beta-cell mass in two different mouse models of beta-cell dysfunction leading to diabetes. The decline of this biomarker precedes the development of hyperglycemia in lean b-Phb2 -/- and obese db/db diabetic mice, where beta-cell loss occurs through two different mechanisms. Additional studies have shown a correlation of 1,5-AG levels with risk of progression of type 1 diabetes (T1DM) in auto-antibody positive children, as well as with glycaemic control in patients with type 2 diabetes (T2DM). The present project will analyse the correlation between functional beta-cell mass and the circulating levels of 1,5-AG in children with obesity with or without T2DM. This should contribute to the evaluation of a novel biomarker of beta-cell mass and function in T2DM.

Conditions

Interventions

TypeNameDescription
OTHERMeasurement of biomarkerMeasurement of blood levels of 1,5-anhydroglucitol

Timeline

Start date
2024-11-22
Primary completion
2028-12-31
Completion
2028-12-31
First posted
2024-11-12
Last updated
2025-04-02

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT06682481. Inclusion in this directory is not an endorsement.